Navigation Links
PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting
Date:12/6/2007

ATLANTA, Dec. 6 /PRNewswire/ -- Data from 11 PROCRIT(R) (Epoetin alfa) studies will be presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition December 8 - 11, 2007.
The data will provide important insights including:

-- the potential impact on the nation's blood supply of limiting the use

of erythropoiesis-stimulating agents (ESAs) for the treatment of

chemotherapy-induced anemia (CIA);

-- the use of PROCRIT in extended dosing regimens;

-- the use of PROCRIT for treatment of transfusion-dependent anemia in

patients with myelodysplastic syndromes (MDS);

-- PROCRIT and real-world practice patterns;

-- PROCRIT in managed care settings; and

-- observational data from the Dosing Outcomes Study of Erythropoiesis-

Stimulating Therapies (DOSE) Registry.

In some cases, the data are from investigational studies and do not reflect current U.S. Food and Drug Administration (FDA)-approved PROCRIT indications or recommended dosage and administration. Please note that all information presented at ASH is embargoed for media release until the data are made available to the public on the ASH Web site.

Data on the Potential Impact on Blood Supply of Limiting ESA Use for Chemotherapy Patients

-- Poster: Impact of Limiting Erythropoiesis-Stimulating Agent Use for

Chemotherapy-Induced Anemia on the United States Blood Supply

Francis Vekeman, M.A., Groupe d'analyse, Ltee, Montreal, Quebec, Canada

Presentation: Monday, December 10, 2007; 5:00pm - 7:00pm; Hall B3 and

B4 in the Georgia World Congress Center (Poster Board Number 115,

Publication Number 2896)

A modeling simulation was employed to estimate the impact of limiting

the use of ESAs for CIA on the U.S. blood supply. The model used a

top-down approach to compare the number of red blood cell units

tra
'/>"/>

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SAN FRANCISCO, Calif., May 16, 2012  Rigel Pharmaceuticals, Inc., ... franchise by focusing on two innovative, comprehensive treatment alternatives ... an inhaled SYK inhibitor, will be entering a Phase ... moderate asthmatic patients. The other, R256, an inhaled IL13 ...
... May 15, 2012   OphthaliX (OTCBB: OPLI) today ... ended March 31, 2012. OphthaliX is an advanced clinical-stage ... treatment of ophthalmic disorders.  Our drug, CF101 (known generically ... indications: dry eye syndrome; glaucoma and uveitis. We are ...
Cached Medicine Technology:Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 2Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 3Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 4OphthaliX Reports First Quarter 2012 Financial Results 2OphthaliX Reports First Quarter 2012 Financial Results 3
(Date:11/28/2014)... 27, 2014 (HealthDay News) -- Celebration can quickly ... on Thanksgiving Day, experts say. Over the last ... have occurred while people were using turkey fryers, according ... have actually cared for a patient who tried to ... be done in any circumstances," Dr. Arthur Sanford, a ...
(Date:11/28/2014)... Not only is the Éminence Organic ... petroleum, parabens and other cancer-causing agents, but they are ... and awareness programs that help in the fight against ... raised an incredible, record-breaking contribution of $30,000 through participation ... the Sweet Red Rose Whip Moisturizer and the company’s ...
(Date:11/28/2014)... 2014 Earlier in the year, ... hugely popular, 2014 MTV Video Music Awards broadcasted ... ground-breaking celebrity centered television advertisements directed at 11.9 ... were estimated by Entertainment Weekly and ... spotlight on celebrities photographed by paparazzi smoking. In ...
(Date:11/28/2014)... A newly released article from Community Health Center ... that will soon be spreading across the United States during ... a brief explanation of what the influenza virus is and ... under the age of 5, adults over the age of ... and lung diseases, asthma, or diabetes, are at higher risk ...
(Date:11/28/2014)... Patten Pecans, based in Lakeland, Georgia, loves ... driving them, they've added a pecan oil to their ... oils, they've found this pecan oil from Oliver ... retaining the buttery pecan notes that are in the ... found in pecans nuts is found in pecan oil, ...
Breaking Medicine News(10 mins):Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... Reporter , THURSDAY, Feb. 24 (HealthDay News) -- While experts ... of centuries past, isolated cases still appear, even in the ... report, a American lab worker died from plague in 2009 ... since 1959 and the first known death from a weakened ...
... men with a rapid rise in PSA have a biopsy ... and the PSA is within the "normal" range. But change ... of prostate cancer, and may lead to many unnecessary biopsies, ... Journal of the National Cancer Institute. Researchers ...
... , THURSDAY, Feb. 24 (HealthDay News) -- A mouse heart ... organ a day after birth, scientists report. With this ... can be found to help the human heart heal itself. ... regeneration, but they,re somehow permanently switched off," said Eric Olson, ...
... Full-term pregnancy has long been associated with a reduced risk ... more times a woman gives birth, the higher her risk ... subtype of the disease. Conversely, women who never give birth ... which has a poorer prognosis than other types of breast ...
... , THURSDAY, Feb. 24 (HealthDay News) -- People are more likely ... Researchers gave a 15-question math test to two groups of ... answers. One group was told that a software problem would ... they hit the space bar, but only they would know if ...
... EAST LANSING, Mich. Michigan State University has ... and food security in Mozambique through increasing the ... enhancing nutrition. The four-year grant, funded by ... to MSU and the University of Florida. The ...
Cached Medicine News:Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:PSA velocity screening for prostate cancer may lead to unnecessary biopsies 2Health News:Scientists Say Newborn Mice Can Regrow Damaged Hearts 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 3Health News:People More Likely to Act Morally Than They Imagine 2Health News:$7.9 million grant to improve food security, nutrition in Mozambique 2
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Duraloc acetabular cup system....
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: